These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7704480)

  • 1. Liposomes in the treatment of infections.
    Bakker-Woudenberg IA; Storm G; Woodle MC
    J Drug Target; 1994; 2(5):363-71. PubMed ID: 7704480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes and lipid carriers in the treatment of microbial infections.
    Bakker-Woudenberg IA; Lokerse AF
    Scand J Infect Dis Suppl; 1990; 74():34-41. PubMed ID: 2097717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-circulating sterically stabilized liposomes in the treatment of infections.
    Bakker-Woudenberg IA; Schiffelers RM; Storm G; Becker MJ; Guo L
    Methods Enzymol; 2005; 391():228-60. PubMed ID: 15721385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system.
    Storm G; ten Kate MT; Working PK; Bakker-Woudenberg IA
    Clin Cancer Res; 1998 Jan; 4(1):111-5. PubMed ID: 9516959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin.
    Schiffelers RM; Storm G; ten Kate MT; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):464-70. PubMed ID: 11158742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
    Patterson TF; Andriole VT
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S63-8. PubMed ID: 2693111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of experimental osteomyelitis by liposomal antibiotics.
    Kadry AA; Al-Suwayeh SA; Abd-Allah AR; Bayomi MA
    J Antimicrob Chemother; 2004 Dec; 54(6):1103-8. PubMed ID: 15486079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
    Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
    J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.
    Allen TM; Mehra T; Hansen C; Chin YC
    Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance of drug carriers in the treatment of visceral leishmaniasis].
    Fusai T; Durand R; Boulard Y; Paul M; Bories C; Rivollet D; Houin R; Deniau M
    Med Trop (Mars); 1995; 55(1):73-8. PubMed ID: 7637615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-circulating liposomes.
    Oku N; Namba Y
    Crit Rev Ther Drug Carrier Syst; 1994; 11(4):231-70. PubMed ID: 7664348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of liposomes as injectable-drug delivery systems.
    Ostro MJ; Cullis PR
    Am J Hosp Pharm; 1989 Aug; 46(8):1576-87. PubMed ID: 2672806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
    Ahmad I; Sarkar AK; Bachhawat BK
    Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.
    Bakker-Woudenberg IA; Lokerse AF; ten Kate MT; Melissen PM; van Vianen W; van Etten EW
    Eur J Clin Microbiol Infect Dis; 1993; 12 Suppl 1():S61-7. PubMed ID: 8477767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.